Decreased serum amyloid β1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1-42 peptide
Decreased serum amyloid β1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1-42 peptide
复制标题
DOI：
10.1016/j.biopsych.2004.12.008
复制
发表时间：
2005-04-01
影响因子：
10.6
通讯作者：
Hampel, H
中科院分区：
文献类型：
--
作者：
Brettschneider, S;Morgenthaler, NG;Hampel, H
背景资料：在阿尔茨海默病（AD）患者中发现的针对淀粉样蛋白β（A β）肽的自身抗体也在一般人群中自然发生，与认知状态无关。我们比较了血清A β（1-42）自身抗体水平（A β（1-42）-AL）的96名AD患者和30名健康老年对照受试者（HC），通过新开发的放射性标记A β（1-42）肽免疫沉淀试验评估其对AD的诊断价值。结果：我们发现AD患者的A β（1-42）-AL显著降低（p = 0.001），与年龄、认知状态和载脂蛋白E β 4携带状态无关。淀粉样β（1-42）自身抗体水平与AD患者的性别相关，女性患者的水平较高。当A β（1-42）自身抗体敏感性（特异性）设定为> 80%时，特异性（敏感性）低于50%以正确分配患者和健康对照受试者。AD中的A β（1-42）抗体。然而，单独血清中的淀粉样蛋白β（1-42）抗体似乎不能用作AD的诊断标志物。
Background: Autoantibodies against amyloid beta (A beta) peptide found in patients with Alzheimer's disease (AD) also occur naturally in the general population independently of the cognitive status.Methods: We compared serum A beta(1-42) autoantibody levels (A beta(1-42)-AL) of 96 AD patients and 30 healthy elderly control subjects (HC), assessing their diagnostic value for AD with a newly developed immunoprecipitation assaywith radiolabeled A beta(1-42) peptide.Results: We found a highly significant decrease of A beta(1-42)-AL in AD patients (p =.001) independently of age, cognitive status, and apolipoprotein E epsilon 4 carrier status. Amyloid beta(1-42) autoantibody levels were correlated with gender in AD, with a higher level occurring in women. When A beta(1-42) autoantibody sensitivity (specificity) was set > 80%, specificity (sensitivity) was below 50% to correctly allocate patients and healthy control subjects.Conclusions: Our data indicate a potentially pathophysiologic decrease of serum. A beta(1-42) antibodies in AD. Amyloid beta(1-42) antibodies in the serum alone, however, seem not to be useful as a diagnostic marker of AD.